Evidence map›Paper›PMID 36881338›Full record

ArticleFunctional & integrative genomics2023

CircAGO2 promotes colorectal cancer progression by inhibiting heat shock protein family B (small) member 8 via miR-1-3p/retinoblastoma binding protein 4 axis.

Xijia Zhu, Xishun Luo, Xiangkai Long, Shiyu Jiang, Xinyang Xie, Qiqi Zhang, Haipeng Wang

Abstract read
PubMed Publisher
In one paragraph

Article in Functional & integrative genomics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.1field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Review
  5. The important role of miR-1-3p in cancers.Journal of translational medicine · 2023
    Review
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 1 institution in 1 country.

Xijia Zhu *Department of Gastrointestinal Surgery, the Second Affiliated Hospital of Guilin Medical University, No. 212 Renmin Road, Lingui District, Guilin, Guangxi, 541100, People's Republic of China.
Xishun Luo *Department of Gastrointestinal Surgery, the Second Affiliated Hospital of Guilin Medical University, No. 212 Renmin Road, Lingui District, Guilin, Guangxi, 541100, People's Republic of China.
Xiangkai LongDepartment of Gastrointestinal Surgery, the Second Affiliated Hospital of Guilin Medical University, No. 212 Renmin Road, Lingui District, Guilin, Guangxi, 541100, People's Republic of China.
Shiyu JiangDepartment of Gastrointestinal Surgery, the Second Affiliated Hospital of Guilin Medical University, No. 212 Renmin Road, Lingui District, Guilin, Guangxi, 541100, People's Republic of China.
Xinyang XieDepartment of Gastrointestinal Surgery, the Second Affiliated Hospital of Guilin Medical University, No. 212 Renmin Road, Lingui District, Guilin, Guangxi, 541100, People's Republic of China.
Qiqi ZhangDepartment of Gastrointestinal Surgery, the Second Affiliated Hospital of Guilin Medical University, No. 212 Renmin Road, Lingui District, Guilin, Guangxi, 541100, People's Republic of China.
Haipeng WangDepartment of Gastrointestinal Surgery, the Second Affiliated Hospital of Guilin Medical University, No. 212 Renmin Road, Lingui District, Guilin, Guangxi, 541100, People's Republic of China. whp197307@163.com.
Guilin Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

This paper was to uncover the mechanism of circular RNA Argonaute 2 (circAGO2) in colorectal cancer (CRC) progression. The expression of circAGO2 was detected in CRC cells and tissues, and the relationship between clinicopathological features of CRC and circAGO2 level was evaluated. The growth and invasion of CRC cells and subcutaneous xenograft of nude mice were measured to evaluate the effect of circAGO2 on CRC development. Bioinformatics databases were applied to analyze levels of retinoblastoma binding protein 4 (RBBP4) and heat shock protein family B 8 (HSPB8) in cancer tissues. The relevance of circAGO2 and RBBP4 expression and the relationship between RBBP4 and HSPB8 during histone acetylation were assessed. The targeting relationship between miR-1-3p and circAGO2 or RBBP4 was predicted and confirmed. The effects of miR-1-3p and RBBP4 on biological functions of CRC cells were also verified. CircAGO2 was upregulated in CRC. CircAGO2 promoted the growth and invasion of CRC cells. CircAGO2 competitively bound to miR-1-3p and regulated RBBP4 expression, thus inhibiting HSPB8 transcription by promoting histone deacetylation. Silencing circAGO2 enhanced miR-1-3p expression and reduced RBBP4 expression, while suppression of miR-1-3p downgraded levels of miR-1-3p, up-regulated RBBP4, and facilitated cell proliferation and invasion in the presence of silencing circAGO2. RBBP4 silencing decreased RBBP4 expression and reduced proliferation and invasion of cells where circAGO2 and miR-1-3p were silenced. CircAGO2 overexpression decoyed miR-1-3p to increase RBBP4 expression, which inhibited HSPB8 transcription via histone deacetylation in HSPB8 promoter region, promoting proliferation and invasion of CRC cells.

Indexed as

Colorectal NeoplasmsHeat-Shock ProteinsMicroRNAsRNA, CircularAnimalsArgonaute ProteinsHistonesHumansMiceMice, NudeMolecular ChaperonesRetinoblastoma-Binding Protein 4AGO2 protein, humanArgonaute ProteinsHeat-Shock ProteinsHistonesHSPB8 protein, humanMicroRNAsMIRN1 microRNA, humanMolecular ChaperonesRBBP4 protein, humanRetinoblastoma-Binding Protein 4RNA, CircularCircular RNA Argonaute 2Colorectal cancerHeat shock protein family B (small) member 8microRNA-1-3pRetinoblastoma binding protein 4

Identifiers

PMID36881338
OpenAlexW4323348886

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.